Patent Attorneys

est. 1931

Patent Attorneys

est. 1931

„CREATIVITY GIVES THE COMPETITIVE EDGE”

This is the philosophy of our clients. We live this philosophy in our services. Our partnership is founded on 85 years of firm experience – going back to 1931. We have changed the legal landscape with innovative approaches before the Düsseldorf courts and the Federal Supreme Court (e.g. Olanzapin – Eli Lilly X ZR 89/07) or before the CJEU  (z.B. Iodosulfuron – Bayer Crop Science C-229/09) and we become successful for our clients in seemingly hopeless cases in opposition and prosecution.

Based on the experience of three generations of patent lawyers and the creativity of completely different individuals with completely different background we design strategic patent portfolios, enforce IP vigorously against infringers and defend the rights of our clients excessively. The key to our success is the continued exchange of ideas and – we like to think out-of-the-box.

The many victories for and against international market leaders confirm our concept.

13 patent attorneys, each with its own history, provide a broad technical and scientific as well as legal expertise. Over the many years we have selected highly qualified cooperation partners in Germany and all over the world.

This is the philosophy of our clients. We live this philosophy in our services. Our partnership is founded on 85 years of firm experience – going back to 1931. We have changed the legal landscape with innovative approaches before the Düsseldorf courts and the Federal Supreme Court (e.g. Olanzapin – Eli Lilly X ZR 89/07) or before the CJEU  (z.B. Iodosulfuron – Bayer Crop Science C-229/09) and we become successful for our clients in seemingly hopeless cases in opposition and prosecution.

Based on the experience of three generations of patent lawyers and the creativity of completely different individuals with completely different background we design strategic patent portfolios, enforce IP vigorously against infringers and defend the rights of our clients excessively. The key to our success is the continued exchange of ideas and – we like to think out-of-the-box.

The many victories for and against international market leaders confirm our concept.

13 patent attorneys, each with its own history, provide a broad technical and scientific as well as legal expertise. Over the many years we have selected highly qualified cooperation partners in Germany and all over the world.

2009 FEDERAL SUPREME COURT

SUCCESS IN HISTORICAL OLANZAPINE CASE

2010 EUROPEAN COURT OF JUSTICE

SUCCESSFUL SPC DEFENCE

KSVR SUCCESS IN LANDMARK DECISION FOR BAYER CROP SCIENCE

2011/2012 FEDERAL SUPREME COURT

SUCCESSFUL DEFENCE OF GEMCITABINE PATENT AT

KSVR SUCCESS IN LANDMARK DECISION FOR BAYER CROP SCIENCE

2013 PATENT AT SUPREME COURT

SUCCESSFUL DEFENSE OF IL1RA

2013

VICTORY IN COFFEE CAPSULE BATTLE FOR ECC Vs NESTLÉ

2014

CONTRACEPTIVE BATTLE RE YASMIN

SUCCESS FOR BAYER VS HEXAL AND TEVA 2014

2015

SPC Battle AMGEN VS TEVA

2016 FEDERAL SUPREME COURT

EQUIVALENCY VICTORY IN ALIMTA/PEMETREXED CASE FOR ELI LILLY

2017

SUCCESSFUL INJUNCTION BASED ON EQUIVALENCY LAW FOR ELI LILLY vs RATIOPHARM

OLG Munich confirms Preliminary Injunction Infringement Decision based on Doctrine of Equivalence

2018 ADMINISTRATIVE COUNCIL LEGISLATION

SUCCESSFUL ATTACK ON EP

Board of Appeal Decision T1063/18 re Valdity of Administrive Council Act declares Rule 28(2) EPC invalid following KSVR TPO reasoning

2019

SUCCESSFUL DEFENSE OF WORLD’S BEST SELLING PHARMACEUTICAL HUMIRA

The patent of the pharmaceutical Humira was attacked by multiple parties in opposition procedures at the European Patent Office questioning inter alia validity of the priority claim. New EPO followed a new approach to assessing priority developed by KSVR

2020 SUPREME COURT

SUCCESSFUL DEFENSE OF FAMOUS ALIMTA/PEMETREXED PATENT

The Alimta/Pemetrexed patent was defended at the Federal Supreme Court and subsequently enforced against various generic companies based on the doctrine of equivalence.

Top ranked in

Legal500 – JUVE – IAM – CHAMBERS – WIRTSCHAFTWOCHE – FOCUS